Human serum albumin: a trusted biomaterial for cell therapy and beyond

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Human serum albumin: a trusted biomaterial for cell therapy and beyond

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Can your raw material strategy meet the safety, consistency, and regulatory demands of cell therapy manufacturing?

This webinar explores how therapeutic-grade Human Serum Albumin (HSA) serves as both an ancillary material and an excipient throughout the cell therapy workflow, from cell isolation to final formulation. Leveraging its USP/EP compliance, GMP manufacturing standards, and extensive viral safety documentation, the session provides a practical perspective on risk-based raw material selection and regulatory alignment.

Using a CAR-T case study, the session shows how plasma-derived HSA improves cell viability, reduces stress, and enhances post-thaw recovery for scalable, regulatory-ready manufacturing.

Attend this webinar to:

Understand HSA’s dual role across cell therapy manufacturing workflows
Review how HSA supports cell viability, stability, and post-thaw recovery
Explore CAR-T examples demonstrating consistency and regulatory alignment
Learn how HSA documentation supports risk management and product registration
Gain perspective on HSA applications beyond cell therapy

Alejandra Gutierrez-Guerrero, PhD

Product Manager, Cell Therapy at Grifols

Alejandra Gutierrez Guerrero, PhD, is a Product Manager in Cell Therapy at Grifols, where she leads product strategy, market analysis, and cross‑functional coordination for cell therapy solutions.

She holds a PhD in Biomedicine from the University of Granada, with a research focus on gene editing technologies for gene therapy. She subsequently completed postdoctoral training at Weill Cornell Medical College (New York, USA) and at the École Normale Supérieure (Lyon, France), working on CRISPR‑based disease models, lentiviral vector optimization, and CAR‑T cell engineering.

Prior to joining Grifols, she led preclinical programs for allogeneic CAR‑T therapies as an R&D Scientist and Project Manager, managing external partners and contributing to regulatory documentation.

Her profile bridges translational cell and gene therapy expertise with product‑ and market‑oriented strategy in the biotherapies field.